pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Dupixent · news · pharmadog
← back to Dupixent
News mentioning Dupixent
27
stories
7d
AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
biospace
8d
New data could widen use of AstraZeneca, Amgen immune disease drug
biopharma dive
10d
Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
fiercebiotech
17d
Regeneron ends eye disease study due to antibody's safety profile
biospace
17d
Regeneron ends eye disease study due to antibody's safety profile
biospace
24d
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
biopharma dive
25d
Regeneron backs $75M series A for antibody upstart Infinimmune
fiercebiotech
29d
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
29d
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
biospace
Aug 5, 26
A COPD drug from China draws $115M in venture funding
biopharma dive
Aug 5, 26
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
Jul 31, 26
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
Jul 31, 26
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
Jul 31, 26
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
Jul 30, 26
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
endpoints
Jul 30, 26
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
biospace
Jul 30, 26
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
biospace
Jul 30, 26
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
Jul 30, 26
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
Jul 24, 26
Sanofi halts development of troubled immune drug in eczema
biopharma dive
Jul 24, 26
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
Jul 24, 26
Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitis
endpoints
Jul 24, 26
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
fiercebiotech
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
Jun 10, 26
Sanofi stops immune drug trial in latest research setback
biopharma dive
May 18, 26
Regeneron immunotherapy combo comes up short in melanoma trial
biopharma dive
Apr 23, 26
Sanofi posts upbeat sales as R&D pressure builds
biopharma dive
